ICER to next assess a batch of ulcerative colitis and cystic fibrosis treatments

9 September 2019

The USA’s Institute for Clinical and Economic Review (ICER) said on Friday that it plans to assess the comparative clinical effectiveness and value of therapies for ulcerative colitis (UC), including:

Entyvio (vedolizumab, subcutaneous and IV formulations, from Takeda (TYO: 4502);
Remicade (infliximab) from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen);
Inflectra (infliximab-dyyb) from Pfizer (NYSE: PFE);
Humira (adalimumab) from AbbVie (NYSE: ABBV);
Simponi (golimumab) from Janssen;
Xeljanz (tofacitinib) from Pfizer; and
Stelara (ustekinumab) from Janssen.

The health technology assessor noted that Takeda is seeking Food and Drug Administration approval for a subcutaneous version of vedolizumab, Janssen is currently pursuing an indication expansion for ustekinumab, and the FDA has already approved the other therapies for UC. The assessment will be publicly discussed during a meeting of the California Technology Assessment Forum in June of 2020, where the independent evidence review panel will deliberate and vote on evidence presented in the ICER’s report.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK